BRIEF published on 06/30/2025 at 14:05, 5 months 18 days ago Promising Phase 1b Results for invIOs's APN401 Cell Therapy in Advanced Tumors Cell Therapy Phase 1b Trial InvIOs GmbH APN401 Advanced Tumors
BRIEF published on 06/30/2025 at 14:05, 5 months 18 days ago Résultats prometteurs de phase 1b pour la thérapie cellulaire APN401 d'invIOs dans les tumeurs avancées Thérapie Cellulaire InvIOs GmbH APN401 Essai De Phase 1b Tumeurs Avancées
PRESS RELEASE published on 06/30/2025 at 14:00, 5 months 18 days ago invIOs reports promising Phase 1b results for cell therapy APN401 in advanced solid tumors invIOs reports successful Phase 1b trial results for APN401 cell therapy in advanced solid tumors, showing safety and efficacy in late-stage cancer patients Solid Tumors Cell Therapy Phase 1b Trial InvIOs APN401
BRIEF published on 12/16/2024 at 15:05, 1 year ago InvIOs to Highlight Oncology Pipeline Progress at JP Morgan Week 2025 Oncology Cancer Research Cell Therapy Glioblastoma InvIOs GmbH
BRIEF published on 12/16/2024 at 15:05, 1 year ago InvIOs mettra en avant les progrès du pipeline oncologique lors de la JP Morgan Week 2025 Thérapie Cellulaire Oncologie Glioblastome Recherche Sur Le Cancer InvIOs GmbH
PRESS RELEASE published on 12/16/2024 at 15:00, 1 year ago invIOs to present progress across oncology pipeline during JP Morgan Week 2025 invIOs GmbH to present progress in oncology pipeline at JP Morgan Week 2025, including updates on glioblastoma treatments INV501 and INV441 in collaboration with DFCI Oncology Pipeline InvIOs GmbH JP Morgan Week 2025 Glioblastoma Treatments DFCI Collaboration
BRIEF published on 10/15/2024 at 10:35, 1 year 2 months ago InvIOs Secures €8.2 Million Series A Funding for Immuno-oncology Innovations Biotechnology Fundraising Clinical Trials Immuno-oncology InvIOs GmbH
BRIEF published on 10/15/2024 at 10:35, 1 year 2 months ago InvIOS obtient un financement de série A de 8,2 millions d'euros pour des innovations en immuno-oncologie Biotechnologie Essais Cliniques Immuno-oncologie Collecte De Fonds InvIOs GmbH
PRESS RELEASE published on 10/15/2024 at 10:30, 1 year 2 months ago invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology invIOs GmbH raises €8.2 million in Series A funding to advance immuno-oncology pipeline progress through 2025, collaborating with Dana-Farber Cancer Institute Series A Funding Immuno-oncology Pipeline Progress InvIOs Dana-Farber Cancer Institute
BRIEF published on 07/17/2024 at 10:05, 1 year 5 months ago InvIOs Selects INV501 Lead Candidate for IND-Enabling Studies in Glioblastoma and Melanoma Cancer Therapy Melanoma Preclinical Studies INV501 Glioblastoma
Published on 12/19/2025 at 00:00, 32 minutes ago LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Published on 12/18/2025 at 23:10, 1 hour 22 minutes ago Air T, Inc. Announces Closing of Regional Express Acquisition
Published on 12/18/2025 at 23:05, 1 hour 27 minutes ago BlackBerry Reports Third Quarter Fiscal Year 2026 Results
Published on 12/18/2025 at 22:45, 1 hour 47 minutes ago Stabilis Solutions Announces Multi-Year Marine Bunkering Agreement with Carnival Coprporation at Proposed Galveston LNG Liquefaction Facility
Published on 12/18/2025 at 22:05, 2 hours 27 minutes ago Abivax fait son entrée au sein de l'indice Nasdaq Biotechnology
Published on 12/18/2025 at 22:05, 2 hours 27 minutes ago Abivax to be Added to Nasdaq Biotechnology Index
Published on 12/18/2025 at 20:09, 4 hours 23 minutes ago EQS-Adhoc: The Grounds Real Estate Development AG: Conversion of the EUR 17 million bond issued in 2023/2024 into a hybrid bond
Published on 12/18/2025 at 19:30, 5 hours 2 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE EN REPONSE ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES DANS LE CADRE DE L’OFFRE PUBLIQUE DE RETRAIT
Published on 12/18/2025 at 19:30, 5 hours 2 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE D’INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES , NOTAMMENT JURIDIQUES, FINANCIERE DE PHAST INVEST
Published on 12/18/2025 at 18:30, 6 hours 2 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 18:30, 6 hours 2 minutes ago Schneider Electric finalise l’opération d’acquisition des 35% restants du capital de sa JV existante en Inde
Published on 12/18/2025 at 17:45, 6 hours 47 minutes ago Cie du Bois Sauvage: Vernietiging eigen aandelen
Published on 12/18/2025 at 17:45, 6 hours 47 minutes ago Damartex réaffirme son éligibilité au PEA-PME
Published on 12/18/2025 at 17:45, 6 hours 47 minutes ago Cie du Bois Sauvage : Cancellation of own shares
